NAS:CDTX (USA) Also trade in: Germany

Cidara Therapeutics Inc

$ 1.6 -0.08 (-4.76%)
Volume: 90,723 Avg Vol (1m): 148,512
Market Cap $: 42.62 Mil Enterprise Value $: -4,850,000.00
P/E (TTM): 0.00 P/B: 1.02
Earnings Power Value 1.47
Net Current Asset Value 1.44
Tangible Book 1.58
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 5.78
Cash-To-Debt ranked lower than
56.77% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CDTX: 5.78
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.13, Med: 10.41, Max: 10000
Current: 5.78
0.13
10000
Debt-to-Equity 0.23
Debt-to-Equity ranked higher than
68.60% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
CDTX: 0.23
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -1.06, Med: 0.16, Max: 0.23
Current: 0.23
-1.06
0.23
Debt-to-EBITDA -0.16
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
CDTX: -0.16
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.37, Med: -0.19, Max: -0.16
Current: -0.16
-1.37
-0.16
Interest Coverage No Debt
Interest Coverage ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
CDTX: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 1
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -6.06
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 13.63%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -113.01
ROE ranked lower than
77.65% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CDTX: -113.01
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -116.66, Med: -72.49, Max: -50.15
Current: -113.01
-116.66
-50.15
ROA % -71.14
ROA ranked lower than
76.20% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CDTX: -71.14
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -668.66, Med: -67.28, Max: -44.4
Current: -71.14
-668.66
-44.4
ROC (Joel Greenblatt) % -8075.91
ROC (Joel Greenblatt) ranked lower than
79.92% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CDTX: -8075.91
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -8075.91, Med: -3167.82, Max: -2537.34
Current: -8075.91
-8075.91
-2537.34
3-Year Total EBITDA Growth Rate -25.40
3-Year EBITDA Growth Rate ranked lower than
87.53% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
CDTX: 8.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -110.5, Med: -51.7, Max: 8.1
Current: 8.1
-110.5
8.1
3-Year EPS w/o NRI Growth Rate 5.30
3-Year EPS w/o NRI Growth Rate ranked higher than
50.72% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
CDTX: 5.3
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 5.3, Max: 6.4
Current: 5.3
0
6.4

» CDTX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CDTX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:TRVN NAS:MACK NAS:OMED NAS:AVXL ROCO:6589 WAR:BIO OTCPK:DGJI LSE:DDDD LSE:ERGO TSE:4572 NAS:KMPH ROCO:4193 LSE:MTFB NAS:INFI XTAE:RDHL FRA:PB9 NAS:SRRA OTCPK:CYDY NAS:CERC NAS:BLPH
Traded in other countries 20D.Germany
Address 6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc functions in the healthcare sector based in the United States. Its business involves the development of novel anti-infectives for the treatment of serious infections, especially caused due to fungus. The company's main drug constitutes echinocandins antifungals in the form of CD101IV and CD101 topical. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis. In addition, Cidara has developed a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious diseases.

Ratios

Current vs industry vs history
PB Ratio 1.02
PB Ratio ranked higher than
83.58% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CDTX: 1.02
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 2.85
Current: 1.02
0
2.85
EV-to-EBIT 0.11
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CDTX: 0.11
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -2.09, Med: 0, Max: 0.33
Current: 0.11
-2.09
0.33
EV-to-EBITDA 0.11
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CDTX: 0.11
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -2.11, Med: 0, Max: 0.36
Current: 0.11
-2.11
0.36
Current Ratio 3.19
Current Ratio ranked higher than
65.92% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CDTX: 3.19
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.71, Med: 7.68, Max: 40.11
Current: 3.19
1.71
40.11
Quick Ratio 3.19
Quick Ratio ranked higher than
66.48% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CDTX: 3.19
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.71, Med: 7.68, Max: 40.11
Current: 3.19
1.71
40.11

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -22.20
3-Year Share Buyback Rate ranked lower than
58.11% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CDTX: -22.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -76.2, Med: -22.2, Max: -17.4
Current: -22.2
-76.2
-17.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.01
Price-to-Tangible-Book ranked higher than
87.58% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
CDTX: 1.01
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.01, Med: 1.75, Max: 2.65
Current: 1.01
1.01
2.65
Earnings Yield (Joel Greenblatt) % 1228.79
Earnings Yield (Greenblatt) ranked lower than
96.58% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CDTX: 1228.79
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -670011.6, Med: 0, Max: 163805.34
Current: 1228.79
-670011.6
163805.34

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 1
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N